Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doripenem vs Imipenem-Cilastatin for Ventilator-Associated Pneumonia
NCT00589693Phase 3Terminated
- Sponsor
- Johnson & Johnson
- Start
- Apr 2008
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of doripenem in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Clinical Cure Rate at the End-of-treatment (EOT) Visit at Day 11. Started Apr 2008; status: terminated.
02
Drugs
doripenem
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT00589693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00589693.